跳到正文
ECA GMP News·AI 评分62

USP发布药品滑石粉石棉检测实施文章,涵盖修订版滑石粉专论与<901>、<1901>章

USP Article: Supporting the Detection of Asbestos in Pharmaceutical Talc

AI 导读

USP发布文章介绍药品滑石粉石棉检测现行要求的实施,面向生产商、供应商与委托检测实验室。文章涵盖2026年6月1日正式生效的修订版USP滑石粉专论,以及<901>药品滑石粉中石棉的检测和<1901>药品滑石粉中石棉检测理论与实践两章。

正文 · 原文

The USP has published an article on the implementation of current requirements for asbestos testing in pharmaceutical talc. The article provides an overview for manufacturers, suppliers and contract testing laboratories. It also includes numerous links to further information on the relevant topics. The article covers: the revised USP Talc monograph, which became official on 1 June 2026; USP Chapters <901> Detection of Asbestos in Pharmaceutical Talc and <1901> Theory and Practice of Asbestos Detection in Pharmaceutical Talc; the implementation of the new requirements by manufacturers, suppliers and contract laboratories.The article is available on the USP website. Webinar: "Talc in Pharma"In response to these developments, ECA has developed a Webinar on Monday, 21 September 2026 from 14:00&ndash;16:00 CEST. During the Webinar, Dr Lance Smallshaw (UCB Biopharma SRL, Belgium), who is also a Board Member of the ECA Analytical Quality Control Group, will cover the following topics: Introduction to talc in pharmaceuticals ECHA classification and scientific basis USP monograph and analytical requirements FDA enforcement and compliance implicationsA Q&A session will follow the presentation, giving participants the opportunity to ask questions.

来源:ECA GMP News · gmp-compliance.org